Beta Bionics, an Irvine, CA-based company which specializes in the development of advanced diabetes management solutions, raised $60M in Series E funding.
The round was led by Wellington Management. Previous investors Eventide Asset Management LLC, certain funds managed by RTW Investments, Sands Capital, Soleus Capital, Omega Funds, Perceptive Advisors, and Marshall Wace also participated.
The company intends to use the funds to support expanded commercialization of the iLet Bionic Pancreas and develop the product pipeline.
Led Beta Bionics is a diabetes management solutions company providing the iLet Bionic Pancreas, which is an autonomous insulin delivery system that streamlines diabetes management and reduces the burden on patients, caregivers and physicians.
